Anti Müllerian Hormon düzeylerinin invitro fertilizasyonda kullanımı
Anti Müllerian Hormon (AMH) glikoprotein yapıda bir molekül olup temel olarak erkek seks diferensiasyonunda regulatuar rol oynamaktadır. Erkekte fetal testisin sertoli hücreleri tarafından salgılanmakta iken, dişilerde gelişmekte olan follikülün granüloza hücreleri tarafından s algılanmaktadır. Erkekte Müllerian kanal regresyonunda rol almakta olup, kadınlarda follikül seçiminin inhibisyonunda rol oynamaktadır. Antimüllerian hormon, erkekte, prenatal ve yeni doğan döneminde yüksek konsantrasyonlarda salınmakta olup, puberte döneminde düzeyi daha düşük seyretmektedir. Kadınlarda ise, puberte döneminde artış göstermeye başlayıp, reprodüktif dönemde en üst düzeye çıkmaktadır. Menopoz döneminde ise azalmaktadır. Follikülogeneziste, primordial follikül evresinden preantral follikül evresine geçiş olan inisiyel seçim aşamasında AMH inhibitor rol oynamaktadır. AMH seviyeleri IVF te; ovarian yanıt belirteci, ovarian rezerv belirteci, Lutealfaz belirteci, IVF outcome belirteci, PCOS tanı / tedaviye yanıt, POF- Kanser tedavisi sonrası ovarian hasar, Non-obstruktifAzospermi ve operatif ovarian hasarın değerlendirilmesinde kullanılabilmektedir.
In vitro fertilization and Anti-Mullerian hormone
Anti-Mullerian hormone (AMH), is a glycoprotein structured molecule. AMH plays an important role in male sex differantiation and female folliculogenesis. It has an inhibitor role infolliculer selection period. It's serum consantrations increase in puberty, decrease in menapose andrnaximun in reproductive period in female. This review describes several studies showing that AMH serum level is avaiable to evaluate ovarian response, ovarian reserve, luteal phase and IVF outcome in IVF practise, and the diagnosis and management of polycistic over disease (PCOD) and primer ovarian failure (POF) due to cancer terapy, and non- obstructive asospermi and operative ovarian injury.
___
- 1. Baarends WM, UiJenbroek JT, Kramer P,
Hoogerbrugge JW, van Leeuwen EC, Themmen
AP, Grootegoed JA . Anti-müllerian hormone and
anti-müllerian hormone type II receptor messengerribonucleicracid expression in rat ovaries during postnatal development, the estrous cycle, and
gonadotropin-induced follicle growth. 1995,136(11), 4951-4562
- 2. Weenen C, Laven JS, Von Bergh AR, Cranfleld
M, Groome NP, Vis ser JA, Kramer P, Fauser BC,
Themmen AP. Anti-Mullerian hormone expression
pattern in the human ovary: potential implications
for initial and cyclic follicle recruitment 2004,
10(2), 77-83
- 3. Themmen AP. Anti-Mu'llerian hormone: its role
infollicular growth initiation and survival and as
an ovarian reserve marker 2005, 34, 18-21
- 4. Rey et al, Human Pathology, 2000, 31, 1202-
1208
- 5. La Marca A, Malmusi S, Giulini S, Tamaro LF,
Orvieto R, Levratti P, Volpe A. Anti-Müllerian
hormone plasma levels in spontaneous menstrual
cycle and during treatment with FSH to induce
ovulation 2004, 19 (12), 2738-2741
- 6. La Marca et al, Hum Reprod, 2006, 21, 2022-
2026
- 7. Serum anti-Mullerian hormone levels: a novel
measure of ovarian reserve. Hum Reprod, 2002,
17(12), 3065-3071
- 8. Penarrubia J, Fabregues F, Manau D, Creus M,
Casals G, Casamitjana R, Carmona F, Vanrell JA,
Balasch J. Basal and stimulation day 5 anti-
Mullerian hormone serum concentrations as
predictors of ovarian response and pregnancy in
assisted reproductive technology cycles stimulated
with gonadotropin-releasing hormone agonist—
gonadotropin treatment. Hum Reprod, 2005, 20(4),
915-922
- 9. Fanchin R, Taieb J, Lozano DH, Ducot B,
Frydman R, BouyerJ. High reproducibility of serum
anti-Mullerian hormone measurements suggests a
multi-staged follicular secretion and strengthens
its role in the assessment of ovarian follicular
status. Hum Reprod, 2005, 20(4), 923-927
- 10. Eldar-Geva T, Ben-Chetrit A, Spitz IM,
Rabinowitz R, Markowitz E, Mimoni T, Gal M,
Zylber-Haran E, Margalioth EJ Dynamic assays
ofinhibin B, anti-Mullerian hormone and estradiol
followin g FSH stimulatio n and ovarian
ultrasonography as predictors oflVF outcome
- Hum Reprod, 2005, 20(11), 3178-3183
- 11. La Marca et al, Hum Reprod Adv Ace, 2006
21,3103-3107.
12. Piltonen T, Morin-Papunen L, Koivunen R,
Perheentupa A, Ruokonen A, Tapanainen JS
- Serum anti-MAVMerian hormone levels remain
high until late reproductive age and decrease
during metformin therapy in women with poly cystic
ovary syndrome. Hum Reprod, 2005, 20(7), 1820-1826
- 13. Serum anti-Mullerian hormone levels during
controlled ovarian hyperstimulation in women
with polycystic ovaries with and without
hyperandrogenism.Hum Reprod, 2005, 20(7), 814-819
- 14. Serum anti-Mullerian hormone expression in
women with premature ovarian failure. Hum
Reprod, 2007, 22(1), 117-123
- 15. Fanichel P, Rey R, Poggioli S, Donzeau M,
Chevallier D, Pointis G. Anti-Mullerian hormone
as a seminal marker for spermatogenesis in non-
obstructive azoospermia. Hum Reprod, 1999,
14(8), 2020-2024
- 16. Fujisawa M, Yamasaki T , Okada H ,
Kamodino S. The significance of anti-Mullerian
hormone concentration in seminal plasma for
spermatogenesis 2002, 17(4), 968-970